<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017142</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00377</org_study_id>
    <nct_id>NCT05017142</nct_id>
  </id_info>
  <brief_title>Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)</brief_title>
  <official_title>Swiss Pediatric Inflammatory Bain Disease Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schweizerische Multiple Sklerose Gesellschaft</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma (Switzerland) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis,&#xD;
      symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease&#xD;
      in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university&#xD;
      hospital in Bern. Further centers all over Switzerland were opened for recruitment in 2021;&#xD;
      Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, and Zurich. The center&#xD;
      in Winterthur is expected to be open for recruitment by autumn 2021. The registry provides&#xD;
      data for national and international monitoring and research. It supports research on&#xD;
      inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians,&#xD;
      researchers, and therapists. The registry aims to improve the treatment of children with&#xD;
      inflammatory brain diseases and optimizing their health care and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Pediatric onset MS and other inflammatory brain diseases (IBrainDs) are severe diseases&#xD;
      affecting children and adolescents in a period of essential brain development. This possibly&#xD;
      leads to a variety of focal neurological deficits as well as early cognitive impairment. In&#xD;
      turn, the cognitive impairment may impact school performance and vocational achievements.&#xD;
&#xD;
      Timely diagnosis and treatment initiation as well as individually tailored management are&#xD;
      important for a favorable disease course. However, the diagnosis of the different IBrainDs&#xD;
      can be challenging, especially in young children, since their first acute inflammation is&#xD;
      often accompanied by unspecific symptoms common to all IBrainDs. A systematic assessment of&#xD;
      similarities and differences between clinical signs, symptoms, and diagnostic workup of&#xD;
      different IBrainDs will enable faster and more reliable diagnosis.&#xD;
&#xD;
      Furthermore, neither epidemiological data nor information on health care management and&#xD;
      disease outcome of pediatric IBrainD patients exist in Switzerland. Therefore, a national&#xD;
      registry is being established, which will allow a deeper understanding of pediatric IBrainD&#xD;
      epidemiology, clinical presentation, and management. Ultimately, the registry will improve&#xD;
      the care of children suffering from an IBrainD in Switzerland.&#xD;
&#xD;
      The Swiss-Ped-IBrainD Registry (title: &quot;Swiss Pediatric Inflammatory Brain Disease Cohort&#xD;
      Study&quot;, project number: 2019-00377) has been approved by the ethics committees of Bern, the&#xD;
      Ethikkommission Nordwest- und Zentralschweiz (EKNZ), the Ethikkommission Ostschweiz (EKOS),&#xD;
      and the ethics committees of Zürich, Lausanne, Geneva, and Bellinzona.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The registry pursues the following goals:&#xD;
&#xD;
        1. Gathering representative, population-based epidemiological data on pediatric IBrainD in&#xD;
           Switzerland.&#xD;
&#xD;
        2. Monitoring treatment, clinical course, education, social aspects, and outcomes of&#xD;
           pediatric IBrainD patients.&#xD;
&#xD;
        3. Providing a platform to facilitate research, national and international collaboration&#xD;
           and exchange of knowledge between experts.&#xD;
&#xD;
      The registry thus addresses the increasing requests for medical trial participation and&#xD;
      promotes the exchange with existing adult registries (e.g., Swiss MS Registry).&#xD;
&#xD;
      Inclusion/exclusion criteria:&#xD;
&#xD;
      All patients living and/or treated in Switzerland with an IBrainD specified in the following&#xD;
      list with a disease onset before the age of 18.&#xD;
&#xD;
        -  Optic neuritis&#xD;
&#xD;
        -  Transverse myelitis&#xD;
&#xD;
        -  Acute disseminated encephalomyelitis&#xD;
&#xD;
        -  Multiple sclerosis&#xD;
&#xD;
        -  Neuromyelitis optica spectrum disorders&#xD;
&#xD;
        -  Anti-NMDA-R associated autoimmune encephalitis&#xD;
&#xD;
        -  Anti-GAD65 associated autoimmune encephalitis&#xD;
&#xD;
        -  Anti-AMPAR-1/2 associated autoimmune encephalitis&#xD;
&#xD;
        -  Anti-Lgi-1 associated autoimmune encephalitis&#xD;
&#xD;
        -  Anti-CASPR-2 associated autoimmune encephalitis&#xD;
&#xD;
        -  Anti-GABAR-1/2 associated autoimmune encephalitis&#xD;
&#xD;
        -  Onconeuronal antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) associated&#xD;
           autoimmune encephalitis&#xD;
&#xD;
        -  Hashimoto encephalopathy&#xD;
&#xD;
        -  CNS vasculitis&#xD;
&#xD;
        -  CNS sarcoidosis&#xD;
&#xD;
        -  CNS Lupus&#xD;
&#xD;
        -  Rasmussen's encephalitis&#xD;
&#xD;
      Excluded are patients with:&#xD;
&#xD;
        1. Neurological symptoms due to infectious diseases of the CNS&#xD;
&#xD;
        2. Genetic/metabolic causes of central demyelinating diseases&#xD;
&#xD;
        3. Neurological symptoms due to Guillain-Barré-Syndrome&#xD;
&#xD;
      Registration of Patients and Collection of Medical Data:&#xD;
&#xD;
      Pediatricians, pediatric neurologists, neurologists, specialists in rehabilitation, and&#xD;
      primary care physicians at the participating centers are responsible to identify children&#xD;
      with the listed IBrainDs during regular medical consultations. Upon identification, treating&#xD;
      physicians inform patients and their parents orally and in writing about the&#xD;
      Swiss-Ped-IBrainD. Patients (and their legal representatives if applicable) who want to&#xD;
      participate must give their informed consent. Once a patient consents to participate, his/her&#xD;
      medical data will be entered in the registry.&#xD;
&#xD;
      The diagnostic workup and treatment of patients continue as usual and are independent from&#xD;
      participation; no examination will be carried out specifically for the Swiss-Ped-IBrainD.&#xD;
&#xD;
      Medical data is collected through the following sources:&#xD;
&#xD;
        -  Medical records and reports&#xD;
&#xD;
        -  Oral/written information from treating physician&#xD;
&#xD;
        -  Oral/written information from patient/family&#xD;
&#xD;
        -  Routine statistics and other medical registries&#xD;
&#xD;
        -  Questionnaires for patients and families The data collection focuses on diagnostic,&#xD;
           follow-up, and relapse variables.&#xD;
&#xD;
      Routine data and linkages:&#xD;
&#xD;
      Communities; Federal Statistical Office (e.g. the birth register, cause of death statistics,&#xD;
      hospital statistics)&#xD;
&#xD;
      Current status:&#xD;
&#xD;
      From 2020-2021, the investigators have included 17 persons diagnosed with an IBrainD.&#xD;
&#xD;
      Funding:&#xD;
&#xD;
        -  Schweizerische Multiple Sklerose Gesellschaft&#xD;
&#xD;
        -  PedNet Bern&#xD;
&#xD;
        -  Roche Pharma (Switzerland) Ltd&#xD;
&#xD;
        -  Novartis Pharma Schweiz AG&#xD;
&#xD;
        -  SwissPedRegistry, University of Bern&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2071</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2071</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>18 Years</target_duration>
  <primary_outcome>
    <measure>Personal data</measure>
    <time_frame>At registration (Life-long; Up to 80 years)</time_frame>
    <description>Registering patient's personal data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Diagnosis of IBrainD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at diagnosis</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Age at diagnosis (months and years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First symptoms</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Symptoms before diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age at first symptoms</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Age at first symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic delay</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Time elapsed between symptom-onset and diagnosis (days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Length of hospitalization at diagnosis or during a relapse (days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rehabilitation</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Length and type of rehabilitation at diagnosis or during a relapse (days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death date</measure>
    <time_frame>Life-long; Up to 80 years</time_frame>
    <description>Date of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death cause</measure>
    <time_frame>Life-long; Up to 80 years</time_frame>
    <description>Cause of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EDSS</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>EDSS change over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Neurostatus</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Neurostatus change over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in medication</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Change of IBrainD medication over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Education</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Evolution of education over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MRI data</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Change in number of CNS lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MRI data</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Change in activity of CNS lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in laboratory test data</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Change in diagnostic markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrophysiological testing</measure>
    <time_frame>Until reaching of adulthood (0 to 18 years)</time_frame>
    <description>Assessment if the patient did undergo electrophysiological testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Future questionnaires</measure>
    <time_frame>Life-long; Up to 80 years; Will mainly concern childhood (until reaching of adulthood; 0 to 18 years)</time_frame>
    <description>Data from validated instrument such as the Pediatric Quality of Life Inventory (PedsQL); Scale from 0-100, where 100 is the best possible outcome and 0 the worst possible outcome.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Optic Neuritis</condition>
  <condition>Transverse Myelitis</condition>
  <condition>Acute Disseminated Encephalomyelitis</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <condition>Anti-NMDAR Encephalitis</condition>
  <condition>Anti-GAD65 Associated Autoimmune Encephalitis</condition>
  <condition>Anti-AMPAR-1/2 Associated Autoimmune Encephalitis</condition>
  <condition>Anti-Lgi-1 Associated Autoimmune Encephalitis</condition>
  <condition>Anti-CASPR-2 Associated Autoimmune Encephalitis</condition>
  <condition>Anti-GABAR-1/2 Associated Autoimmune Encephalitis</condition>
  <condition>Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis</condition>
  <condition>Hashimoto Encephalitis</condition>
  <condition>CNS Vasculitis</condition>
  <condition>CNS Sarcoidosis</condition>
  <condition>CNS Lupus</condition>
  <condition>Rasmussen Encephalitis</condition>
  <arm_group>
    <arm_group_label>Patient population</arm_group_label>
    <description>Children, adolescents and adults diagnosed with an IBrainD before age 18, who are born, treated or living in Switzerland</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients living and/or treated in Switzerland with a listed IBrainD and a disease onset&#xD;
        before the age of 18.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients living and/or treated in Switzerland with an IBrainD specified in the&#xD;
        following list with a disease onset before the age of 18.&#xD;
&#xD;
          -  Written informed consent by patients (and/or legal representative(s), if applicable)&#xD;
&#xD;
          -  Optic Neuritis&#xD;
&#xD;
          -  Transverse Myelitis&#xD;
&#xD;
          -  Acute disseminated encephalomyelitis&#xD;
&#xD;
          -  Multiple Sclerosis&#xD;
&#xD;
          -  Neuromyelitis Optica Spectrum Disorders&#xD;
&#xD;
          -  Anti-NMDA-R Encephalitis&#xD;
&#xD;
          -  Anti-GAD65 Associated Autoimmune Encephalitis&#xD;
&#xD;
          -  Anti-AMPAR-1/2 Associated Autoimmune Encephalitis&#xD;
&#xD;
          -  Anti-Lgi-1 Associated Autoimmune Encephalitis&#xD;
&#xD;
          -  Anti-CASPR-2 Associated Autoimmune Encephalitis&#xD;
&#xD;
          -  Anti-GABAR-1/2 Associated Autoimmune Encephalitis&#xD;
&#xD;
          -  Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated&#xD;
             Autoimmune Encephalitis&#xD;
&#xD;
          -  Hashimoto Encephalopathy&#xD;
&#xD;
          -  CNS Vasculitis&#xD;
&#xD;
          -  CNS Sarcoidosis&#xD;
&#xD;
          -  CNS Lupus&#xD;
&#xD;
          -  Rasmussen Encephalitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological symptoms due to infectious diseases of the CNS&#xD;
&#xD;
          -  Genetic/metabolic causes of central demyelinating diseases&#xD;
&#xD;
          -  Neurological symptoms due to Guillain-Barré-Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Bigi, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ISPM, University of Bern, Bern; University Children's Hospital, University of Bern, Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Bigi, PD MD</last_name>
    <role>Study Director</role>
    <affiliation>ISPM, University of Bern, Bern; University Children's Hospital, University of Bern, Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia E Kuehni, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>ISPM, University of Bern, Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorena F Hulliger, MSc</last_name>
    <phone>0316845678</phone>
    <phone_ext>+41</phone_ext>
    <email>lorena.hulliger@ispm.unibe.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Capone Mori</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susi Strozzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Switzerland</name>
      <address>
        <city>St.Gallen</city>
        <state>Saint Gallen</state>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Maier</last_name>
    </contact>
    <contact_backup>
      <last_name>Tanja Wachinger</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pediatric Institute of Southern Switzerland, Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Goeggel Simonetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Lausanne (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Kalser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <state>Zurich</state>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regula Schmid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Basel, UKBB</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Dill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital, Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Bigi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Social and Preventive Medicine, University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena F Hulliger</last_name>
    </contact>
    <contact_backup>
      <last_name>Claudia E Kuehni</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Geneva (HUG)</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Garcia-Tarodo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bauder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Hackenberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.swiss-ped-ibraind.ch</url>
    <description>Website of the registry</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
    <mesh_term>Anti-N-Methyl-D-Aspartate Receptor Encephalitis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Vasculitis, Central Nervous System</mesh_term>
    <mesh_term>Encephalomyelitis, Acute Disseminated</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers who wish to develop a nested study need to submit a proposal to the Swiss-Ped-IBrainD committee and request permission. A concept sheet describing the planned analyses must be approved by the Swiss-Ped-IBrainD committee. Nested studies might need separate ethics permission.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

